CR10384A - Formulaciones de emulsion estable - Google Patents
Formulaciones de emulsion estableInfo
- Publication number
- CR10384A CR10384A CR10384A CR10384A CR10384A CR 10384 A CR10384 A CR 10384A CR 10384 A CR10384 A CR 10384A CR 10384 A CR10384 A CR 10384A CR 10384 A CR10384 A CR 10384A
- Authority
- CR
- Costa Rica
- Prior art keywords
- stable emulsion
- emulsion formulations
- calcimimetics
- phlebitis
- irritants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a formulaciones inyectables de agentes irritantes, tales como calcimimeticos, que son farmaceuticamente estables y demuestran una incidencia reducida de irritacion, dolor, flebitis, precipitacion y hemolisis despues que se inyectan.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79382506P | 2006-04-20 | 2006-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10384A true CR10384A (es) | 2008-11-11 |
Family
ID=38537687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10384A CR10384A (es) | 2006-04-20 | 2008-10-21 | Formulaciones de emulsion estable |
Country Status (14)
Country | Link |
---|---|
US (1) | US8779004B2 (es) |
EP (1) | EP2010150A2 (es) |
JP (1) | JP5199239B2 (es) |
KR (1) | KR20080110681A (es) |
CN (1) | CN101437490A (es) |
AU (1) | AU2007240317B2 (es) |
BR (1) | BRPI0710814A2 (es) |
CA (1) | CA2648939C (es) |
CR (1) | CR10384A (es) |
EA (1) | EA200802166A1 (es) |
MX (1) | MX2008013339A (es) |
NO (1) | NO20084368L (es) |
WO (1) | WO2007124465A2 (es) |
ZA (1) | ZA200808773B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1746976T3 (pl) | 2004-05-03 | 2017-09-29 | Merrimack Pharmaceuticals, Inc. | Liposomy przydatne w systemie podawania leków |
CA2657028A1 (en) * | 2006-07-10 | 2008-01-17 | Indiana University Research And Technology Corporation | Methods for treating cystic kidney diseases |
EP2114390A2 (en) * | 2006-12-15 | 2009-11-11 | Ruprecht-Karls-Universität Heidelberg | Methods for treating podocyte-related disorders |
AU2008233088B2 (en) * | 2007-03-30 | 2013-09-26 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
AU2009228069B9 (en) * | 2008-03-28 | 2014-07-10 | Amgen Inc. | Calcimimetic compound for use in the treatment of epithelial injury |
JP5468221B2 (ja) * | 2008-08-04 | 2014-04-09 | 株式会社 メドレックス | 難溶性薬物の静注用分散製剤 |
WO2010042642A1 (en) * | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
WO2011146583A2 (en) * | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
WO2012039768A2 (en) * | 2010-09-24 | 2012-03-29 | Texas Southern University | Itraconazole formulations |
US8658676B2 (en) * | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
US20120213855A1 (en) * | 2011-02-17 | 2012-08-23 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
US9623087B2 (en) | 2011-11-30 | 2017-04-18 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
EP2858513B1 (en) * | 2012-06-07 | 2016-11-23 | Cargill, Incorporated | Pumpable fat compositions, use in feed and method for reducing their viscosity. |
CA2878895A1 (en) * | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
CN102895187B (zh) * | 2012-09-13 | 2015-05-06 | 西安力邦制药有限公司 | 注射用本芴醇脂肪乳的制备及其在疟疾治疗中的应用 |
ES2767151T3 (es) * | 2012-10-24 | 2020-06-16 | Cargill Inc | Composición de emulsionante que contiene fosfolípidos |
KR101951933B1 (ko) * | 2013-03-12 | 2019-02-25 | 주식회사 아리바이오 | 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법 |
CN103142477B (zh) * | 2013-04-08 | 2015-09-30 | 薛巍 | 一种缓释秋水仙碱的含纳米载体微乳制剂的制备方法 |
CN106714787A (zh) * | 2014-09-25 | 2017-05-24 | 富士胶片株式会社 | 含丙泊酚的水包油型乳液组合物及其制造方法 |
IL255148B2 (en) | 2015-04-29 | 2023-04-01 | Radius Pharmaceuticals Inc | 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation |
SG10201912568PA (en) | 2015-10-16 | 2020-02-27 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
KR101744203B1 (ko) * | 2016-01-12 | 2017-06-20 | (주)노터스생명과학 | 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물 |
CN105769765A (zh) * | 2016-03-22 | 2016-07-20 | 辅必成(上海)医药科技有限公司 | 己酸羟孕酮脂肪乳注射液 |
KR101898282B1 (ko) * | 2016-05-24 | 2018-09-13 | 주식회사 고려비엔피 | 항생제의 서방형 수의학적 조성물 및 이의 제조방법 |
CN117417263A (zh) | 2017-01-05 | 2024-01-19 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
CN109200024A (zh) * | 2017-07-07 | 2019-01-15 | 江苏恒瑞医药股份有限公司 | 西那卡塞药物组合物及其医药用途 |
CN109953979A (zh) * | 2017-12-25 | 2019-07-02 | 江苏恒瑞医药股份有限公司 | 西那卡塞药物组合物及其医药用途 |
CN112423844A (zh) | 2018-07-04 | 2021-02-26 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
KR102158824B1 (ko) * | 2018-09-27 | 2020-09-23 | 한국화학연구원 | 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제 |
AU2019370565A1 (en) * | 2018-11-02 | 2021-06-24 | Ampersand Biopharmaceuticals, Inc. | Management of risk of cation overload and electrolyte imbalance with topically applied buffers |
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR511940A (fr) | 1916-12-08 | 1921-01-07 | Rene Emile Trottier | Dispositif pour la commande des appareils destinés au classement ou à la séparation des matières solides de tous genres |
JPS60258110A (ja) * | 1984-06-05 | 1985-12-20 | Daigo Eiyou Kagaku Kk | 静脈注射可能なプロゲステロン乳化注射液 |
US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5688938A (en) | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
MX9204881A (es) | 1991-08-23 | 1993-04-01 | Nps Pharma Inc | Composicion farmaceutica que comprende moleculas activas, receptoras de calcio. |
US5763569A (en) | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
ES2218531T3 (es) * | 1991-08-23 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Arilalquilaminas activas sobre los receptores del calcio. |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5858684A (en) | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
KR100296899B1 (ko) | 1993-02-23 | 2001-10-24 | 쉘비 칼베르그 모르스 | 칼슘수용체활성분자 |
US5962314A (en) | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
PT1203761E (pt) * | 1994-10-21 | 2005-04-29 | Nps Pharma Inc | Compostos activos do receptor de calcio |
EP1258471B1 (en) | 1996-05-01 | 2007-01-24 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
AU731146C (en) | 1996-05-01 | 2005-02-03 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
US6362231B1 (en) | 1996-07-08 | 2002-03-26 | Nps Pharmaceuticals, Inc. | Calcium receptor active compounds |
TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
NZ503513A (en) * | 1997-09-18 | 2004-12-24 | Skyepharma Inc | Sustained-release liposomal anesthetic compositions |
US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
CN1221249C (zh) * | 1998-08-19 | 2005-10-05 | 斯凯伊药品加拿大公司 | 普鲁泊福的可注射水分散体 |
US6172091B1 (en) | 1998-10-14 | 2001-01-09 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-Disubstituted cyclopropanes |
FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
JP2003535884A (ja) * | 2000-06-16 | 2003-12-02 | スカイファーマ・カナダ・インコーポレーテッド | プロポフォールの改善された注射可能な分散物 |
FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
US6916956B2 (en) | 2000-08-11 | 2005-07-12 | Japan Tobacco, Inc. | Calcium receptor antagonist |
FR2820136A1 (fr) | 2001-01-26 | 2002-08-02 | Aventis Pharma Sa | Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
US7176322B2 (en) * | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
CA2494700C (en) | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
US20050101576A1 (en) | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US20060134145A1 (en) * | 2002-12-06 | 2006-06-22 | Otsuka Pharmaceutical Factory, Inc. | Propofol-containing fat emulsions |
DE602004024668D1 (de) | 2003-04-23 | 2010-01-28 | Japan Tobacco Inc | CaSR-ANTAGONIST |
CN1225242C (zh) * | 2003-05-21 | 2005-11-02 | 浙江天皇药业有限公司 | 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法 |
CA2527203C (en) | 2003-05-28 | 2010-08-17 | Japan Tobacco Inc. | Casr antagonist |
DE602004023509D1 (de) * | 2003-07-23 | 2009-11-19 | Theravance Inc | Pharmazeutische zusammensetzungen eines kurzwirkenden sedativen hypnosemittels |
AU2006227429A1 (en) | 2005-03-17 | 2006-09-28 | Amgen Inc. | Methods of decreasing calcification |
FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
EP1882684B1 (en) | 2005-05-19 | 2014-12-10 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
AU2006285080B2 (en) | 2005-09-02 | 2012-05-03 | Amgen Inc. | Methods of modulating intestinal fluid balance |
EP2114390A2 (en) | 2006-12-15 | 2009-11-11 | Ruprecht-Karls-Universität Heidelberg | Methods for treating podocyte-related disorders |
-
2007
- 2007-04-20 CA CA2648939A patent/CA2648939C/en active Active
- 2007-04-20 KR KR1020087027937A patent/KR20080110681A/ko not_active Application Discontinuation
- 2007-04-20 EP EP07761072A patent/EP2010150A2/en not_active Withdrawn
- 2007-04-20 CN CNA2007800140077A patent/CN101437490A/zh active Pending
- 2007-04-20 US US11/738,444 patent/US8779004B2/en active Active
- 2007-04-20 BR BRPI0710814-1A patent/BRPI0710814A2/pt not_active IP Right Cessation
- 2007-04-20 EA EA200802166A patent/EA200802166A1/ru unknown
- 2007-04-20 WO PCT/US2007/067155 patent/WO2007124465A2/en active Application Filing
- 2007-04-20 AU AU2007240317A patent/AU2007240317B2/en active Active
- 2007-04-20 MX MX2008013339A patent/MX2008013339A/es active IP Right Grant
- 2007-04-20 JP JP2009506810A patent/JP5199239B2/ja active Active
-
2008
- 2008-10-14 ZA ZA200808773A patent/ZA200808773B/xx unknown
- 2008-10-17 NO NO20084368A patent/NO20084368L/no not_active Application Discontinuation
- 2008-10-21 CR CR10384A patent/CR10384A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009534425A (ja) | 2009-09-24 |
US8779004B2 (en) | 2014-07-15 |
ZA200808773B (en) | 2009-07-29 |
EP2010150A2 (en) | 2009-01-07 |
WO2007124465A2 (en) | 2007-11-01 |
CA2648939A1 (en) | 2007-11-01 |
MX2008013339A (es) | 2009-01-26 |
CA2648939C (en) | 2014-07-08 |
WO2007124465A3 (en) | 2008-04-10 |
BRPI0710814A2 (pt) | 2011-08-16 |
CN101437490A (zh) | 2009-05-20 |
AU2007240317B2 (en) | 2012-11-29 |
EA200802166A1 (ru) | 2009-06-30 |
NO20084368L (no) | 2008-11-17 |
JP5199239B2 (ja) | 2013-05-15 |
KR20080110681A (ko) | 2008-12-18 |
AU2007240317A1 (en) | 2007-11-01 |
US20070249520A1 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10384A (es) | Formulaciones de emulsion estable | |
GT200800276A (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
DOP2016000298A (es) | Pirazolopiridinas y pirazolopirimidinas | |
ECSP13011139A (es) | Anticuerpos contra la angiopoyetina 2 humana | |
BR112012018345A2 (pt) | "compostos de heteroarila, bem como composições e usos dos mesmos" | |
EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
MX2011011514A (es) | Formulaciones de canabidiol y metodos para utilizarlas. | |
BRPI0914682B8 (pt) | compostos de heteroarila e composições compreendendo os referidos compostos | |
NI201200038A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
DK2148670T3 (da) | Titrering af tapentadol | |
CR20110466A (es) | Anticuerpos biespecíficos anti-erbb-3/anti-c-met | |
BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
EA201291050A1 (ru) | Комбинация лекарств с протеинсвязывающими пролекарствами | |
BRPI0916069A2 (pt) | "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição" | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
EA201170512A1 (ru) | Композиция для перорального введения | |
NI201100227A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica. | |
CR11406A (es) | Conjugados de neurturina novedosos para uso farmaceutico | |
PA8846401A1 (es) | Sinergismo antibiótico | |
DOP2013000115A (es) | Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma | |
ATE552832T1 (de) | Antidepressivum-propharmaka | |
GT200500386A (es) | Composicion que comprende una epotilona y metodos para producir dicha composicion | |
BR112012028506A2 (pt) | "composições que compreenden extratos de abrótano ( artemisia abrotanum) e um composto de amina" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |